Abstract: Objective To explore and evaluate the histological and serological efficacy of existing?medicine of insulin sensitizers in the clinical treatment and effect of nonalcoholic steatohepatitis (NASH).Methods Chinese and English database were electronically searched for the goal of collecting randomized clinical placebo trials (RCTs) on existing insulin sensitizers in the clinical treatment of NASH. Two different researchers independently screened these studies, collected data from them using the same forms and gave judgment independently of the risk of bias on these chosen clinical studies above. After then, Meta-analysis was performed precisely by RevMan5.3 software on computer.Results A total of 8 articles including 750 qualified researched subjects with NASH were finally chosen. And the results of analysis revealed that insulin sensitizers were able to alleviate liver fibrosis (RR=1.53, 95%CI [1.09, 2.14], P<0.05), steatosis (RR=2.29, 95%CI [1.76, 2.98], P<0.05), hepatocellular ballooning (RR=1.77, 95%CI [1.30, 2.42], P<0.05) and serological ALT (change value MD=-18.42, 95%CI [-29.79, -7.05], terminal value SMD=-1.01, 95%CI [-1.46, -0.56], P<0.05), AST (change value MD=-8.26, 95%CI [-15.12, -1.39], terminal value MD=-15.09, 95%CI [-21.12, -9.07], P<0.05), TG (SMD=-0.46, 95%CI [-0.65, -0.27], P<0.05), FPG (change value SMD=-0.62, 95%CI [-0.98, -0.26], Terminal value SMD=-0.50, 95%CI [-0.93, -0.07], P<0.05), FINS (SMD=-0.77, 95%CI [-1.11, -0.44], P<0.05) indicators, compared with the placebo group, but they could not give a substantial improvement in lobular inflammation (RR=1.53, 95%CI[0.92, 2.54],P>0.05), TC (SMD =-0.21, 95%CI[-0.63, 0.21], P>0.05) and BMI (change value MD=0.06, 95%CI [-1.53, 1.64], terminal value MD=-0.33, 95%CI [-1.44, 0.78], P>0.05) indicators.Conclusion Insulin sensitizer has a certain efficacy in the treatment of NASH, and has a good effect in improving liver histology and serological indicators.

Key words: Biguanide, Thiazolidinedione, Non-alcoholic steatohepatitis, Meta-analysis